Close Menu

FRET

By Ben Butkus
Biosearch Technologies said today that it has acquired worldwide rights from the University of Medicine and Dentistry of New Jersey to patents covering "non-FRET" nucleic acid probe technology.

The new test will be based on real-time PCR using fluorescence resonance energy transfer probes for detection.

The scientist has founded consulting firm Perpetual Genomics to license the technology, which would be a "true universal library" of extremely short FRET-based PCR probes that could allow manufacturers to sell probes fractionally and significantly reduce their cost.

Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.

Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.

A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.

In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.